You are here: Industry Insights > Linzess

News List

Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS (linaclotide) 72 mcg Dosage Strength firstwordpharma
May 27, 2021
IRWD, announced today that, with its partner AbbVie Inc., providing a license to Teva's ANDA seeking approval to market a generic version of 72 mcg LINZESS® (linaclotide) prior to the expiration of the companies' applicable patents.
AstraZeneca amends collaboration with Ironwood for Linzess in China worldpharmanews
September 20, 2019
AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong, S.A.R., China and China Macau, S.A.R., China for Linzess (linaclotide) ...
Ironwood and Allergan settle Linzess patent litigation with Mylan pharmaceutical-technology
January 07, 2019
Ironwood Pharmaceuticals and Allergan have entered an agreement with Mylan Pharmaceuticals to settle patent litigations over generic versions of Linzess (linaclotide) medicine.....
Linzess Approved in Japan for Additional Indication americanpharmaceuticalreview
August 22, 2018
Astellas Pharma and Ironwood Pharmaceuticals announced approval has been obtained in Japan for the guanylate cyclase-C receptor agonist Linzess Tablets 0.25 mg (linaclotide) for the additional indication of chronic constipation.
Ironwood zeroes in on primary care doctors with new gout combo med Duzallo fiercepharma
August 24, 2017
Ironwood's Duzallo won FDA approval earlier this week, and the company plans to promote it to 30,000 to 50,000 primary care physicians.